Boehringer Ingelheim fined $125,000 for conduct breach

According to the committee’s quarterly report, released on Friday, the website was the subject of complaints from the NSW Therapeutic Advisory Group, which argued it included “statements which were intended to promote the use and supply of a prescription product”.

The company argued the site made no mention of any product name and was simply designed to “inform doctors and patients of the Government’s decision, contrary to the advice of the PBAC, to delay the listing of a new stroke medication”.